An Investigational Immuno-therapy Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Solid Cancers That Are Advanced or Have Spread

Official Title

Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumours

Summary:

The purpose of this study is to evaluate the safety and effectiveness of experimental medication BMS-986207 by itself, in combination with Nivolumab, and in combination with both nivolumab and ipilimumab in participants with solid cancers that are advanced or have spread.

Trial Description

Primary Outcome:

  • Incidence of Adverse Events (AEs)
  • Incidence of Serious Adverse Events (SAEs)
  • Incidence of AEs meeting protocol-defined dose limiting toxicity (DLT) criteria
  • Incidence of AEs leading to discontinuation
  • Incidence of deaths
  • Incidence of clinically significant changes in clinical laboratory results: Hematology tests
  • Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests
  • Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests
  • Objective response rate (ORR)
  • Median duration of response (mDOR)
  • Progression-free survival rate (PFSR) at 24 weeks by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 by Investigator
Secondary Outcome:
  • Objective response rate (ORR)
  • Median duration of response (mDOR)
  • Progression-free survival rate (PFSR) at 24 weeks by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
  • Maximum observed serum concentration (Cmax)
  • Time of maximum observed serum concentration (Tmax)
  • Area under the serum concentration-time curve from time zero to time of last quantifiable concentration AUC(0-T)
  • Area under the concentration-time curve in one dosing interval AUC(TAU)
  • Observed concentration at the end of a dosing interval (Ctau)
  • Total body clearance (CLT)
  • Average concentration over a dosing interval (Css-avg)
  • Accumulation Index (AI)
  • Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALFeff)
  • Trough observed serum concentrations (Ctrough)
  • Incidence of anti-drug antibody (ADA)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society